Skip to main content

TNF inhibitor

RT @AkhilSoodMD: Abstr #2192 risk of serious infxn in newborns of mothers on TNFi by placental transfer
- % serious infe

Akhil Sood MD AkhilSoodMD

3 weeks 1 day ago
Abstr #2192 risk of serious infxn in newborns of mothers on TNFi by placental transfer - % serious infection in TNFi in high vs low placental transfer (2.1% vs 1.6%) - HR (high vs low) 0.98 (95% CI 0.36-2.61) - No significant difference in risk of serious infxn @RheumNow #ACR22 https://t.co/7Lfpf7PERu
RT @drdavidliew: Which is better for CV risk in RA:
triple therapy DMARDs or TNFi?

TARGET study
n=159 using PET/CT sur

David Liew drdavidliew

3 weeks 1 day ago
Which is better for CV risk in RA: triple therapy DMARDs or TNFi? TARGET study n=159 using PET/CT surrogate (endpoint responsiveness👀) - either led to benefit - both equally good - benefit *not* linked to change in DAS28 A direct CV effect of RA Rx? ABST2215 #ACR22 @RheumNow https://t.co/4FPvSbfGsD
RT @RichardPAConway: Flatman et al. Risk of infections in children with third trimester TNFi use, high vs low (CTZ, ETN)

Richard Conway RichardPAConway

3 weeks 1 day ago
Flatman et al. Risk of infections in children with third trimester TNFi use, high vs low (CTZ, ETN) placental transfer. No difference but wide CIs, aHR 0.98 (0.36, 2.61) @RheumNow #ACR22 Abstr#2192 https://t.co/350UxX9bkL https://t.co/29uOtek8w7
RT @drdavidliew: Are TNFi or IL-6Ri safe in rheumatic irAEs from ICI Rx?

Multiple big US centers retrospective:
TNFi, I

David Liew drdavidliew

3 weeks 1 day ago
Are TNFi or IL-6Ri safe in rheumatic irAEs from ICI Rx? Multiple big US centers retrospective: TNFi, IL-6Ri vs MTX p>0.05, but may be approx 2x risk of cancer progression Has made me more cautious about TNFi, IL-6Ri - use MTX when you can Lovely work! ABST1669 #ACR22 @RheumNow https://t.co/cfAT1pQZ7I
RT @JulianSegan: Maya Buch on major adverse CV events in tofa vs TNFi. Post-hoc analysis of phase 3b/4 data looking at c

Julian Segan JulianSegan

3 weeks 1 day ago
Maya Buch on major adverse CV events in tofa vs TNFi. Post-hoc analysis of phase 3b/4 data looking at cohort enriched for CV events. @RheumNow #ACR22 #LateBreaking
RT @ericdeinmd: L06 #ACR22 ORAL Surveillance Updates!
Composite of all ischemic CV events and HF did NOT show difference

Eric Dein ericdeinmd

3 weeks 1 day ago
L06 #ACR22 ORAL Surveillance Updates! Composite of all ischemic CV events and HF did NOT show difference b/w TOFA vs TNFi But, MACE numerically higher with Tofa w/ h/o ASCVD Highest CV risk in TOFA 10 mg BID, 2/2 VTE risk Most important risk is pt's individual risks @RheumNow https://t.co/jPPX7f5GRE
RT @RichardPAConway: Guimarães et al Portugese registry data suggests similar retention rates in change of MOA compared

Richard Conway RichardPAConway

3 weeks 1 day ago
Guimarães et al Portugese registry data suggests similar retention rates in change of MOA compared to 2nd TNFi following failure of 1st TNFi. @RheumNow #ACR22 Abstr#2149 https://t.co/Er2FKwYdRv https://t.co/uMPSfMkjfa
RT @RichardPAConway: Ogdie @AlexisOgdie et al. CorEvitas, PsA treatment after 1st line TNFi failure. Switching MOA proba

Richard Conway RichardPAConway

3 weeks 1 day ago
Ogdie @AlexisOgdie et al. CorEvitas, PsA treatment after 1st line TNFi failure. Switching MOA probably more effective @RheumNow #ACR22 Abstr#1600 https://t.co/vy8gxDaYxZ https://t.co/NmkESbSNfL
×